UBS Maintains Neutral on Accendra Health, Lowers Price Target to $1.5

Benzinga Newsdesk www.benzinga.com Negative 80.3%

Neg 80.3% Neu 0% Pos 0%

UBS analyst Kevin Caliendo maintains Accendra Health (NYSE:ACH) with a Neutral and lowers the price target from $4.5 to $1.5.